A randomised controlled trial of outpatient Morita therapy for clients with anxiety

A randomised controlled trial of outpatient Morita therapy for clients with anxiety - A randomised controlled trial of outpatient Morita therapy for clients with anxiety

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000041277

Enrollment

140

Registered

2020-08-01

Start date

2020-09-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety disorders, obsessive-compulsive and related disorders in the DSM-5, or patient/client-reported anxiety equivalent to them.

Interventions

Intervention 1: A standardised and protocolised outpatient Morita therapy Frequency: Weekly Number of therapy sessions: 12 over 3 months (minimum), up to 4 months Duration: 50 minutes per sessi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Individuals who: - meet the criteria for Shinkeishitsu (Equivalent to anxiety, and obsessive-compulsive and related disorders in DSM-5), or report anxiety equivalent to them (but not yet been given a formal diagnosis) - have never received outpatient Morita therapy - are available and able to attend a total of 12 sessions

Exclusion criteria

Exclusion criteria: Active Individuals who: - are self-injurious/harming - are actively suicidal - are diagnosed with developmental disabilities

Design outcomes

Primary

Measure	Time frame
Primary outcome measure: The Generalized Anxiety Disorder (GAD-7)	—

Secondary

Measure	Time frame
Secondary outcome measures: The Patient Health Questionnaire (PHQ)-9 the Japanese General Health Questionnaire (GHQ-12) Self-Kindness Subscale of the Self-Compassion Scale the Japanese version of the Sheehan Disability Scale The Morita Attitudinal Scale for Arugamama (MASA) The outcome measures will be routinely administered to both treatment and control groups, at the pre- (1st session), mid- (6th session), and post treatment (12th session) time points. Follow-up administrations of the measures will be conducted only with the treatment group at 3, 6, 12 months post-treatment time points. Qualitative evaluation: Semi-structured interviews will be conducted with both treatment and control groups at the exact same time points as the administrations of the outcome measures. : Interview questions: (a) What are you anxious about at the present moment?, (b) What was it like for you to take actions? (c) What do you think of yourself now?	—

Measure

Time frame

Secondary outcome measures: The Patient Health Questionnaire (PHQ)-9 the Japanese General Health Questionnaire (GHQ-12) Self-Kindness Subscale of the Self-Compassion Scale the Japanese version of the Sheehan Disability Scale The Morita Attitudinal Scale for Arugamama (MASA) The outcome measures will be routinely administered to both treatment and control groups, at the pre- (1st session), mid- (6th session), and post treatment (12th session) time points. Follow-up administrations of the measures will be conducted only with the treatment group at 3, 6, 12 months post-treatment time points. Qualitative evaluation: Semi-structured interviews will be conducted with both treatment and control groups at the exact same time points as the administrations of the outcome measures. : Interview questions: (a) What are you anxious about at the present moment?, (b) What was it like for you to take actions? (c) What do you think of yourself now?

—

Countries

Japan

Contacts

Public ContactSaki Kaneko

Jikei University School of Medicine Department of Psychiatry

s.kaneko@jikei.ac.jp03-3480-1151ext.3171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026